[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:follicular-helper-t-cell-lymphoma-angioimmunoblastic-type":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":105,"states":106},"Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type",15,12,[8,16,23,30,36,42,48,55,61,67,73,79,85,92,98],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06756308","A Study of Enasidenib in People With T-Cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-03T02:37:16.921019Z","2026-05-05T02:43:27.511255Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06724237","Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy",[20],"Phase 3","2026-08-26T02:18:27.904411Z","2026-05-13T02:55:06.567458Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06393738","A Study of ARV-393 in Relapsed\u002FRefractory Non-Hodgkin Lymphoma.",[27],"Phase 1","2026-08-26T02:17:36.611194Z","2026-05-05T02:43:29.734935Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[20],"2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.764159Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT03017820","A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma",[27],"2026-08-26T02:19:05.360997Z","2026-06-16T05:54:07.906191Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05079282","Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma",[27],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:29.642831Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT03719105","Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia\u002FLymphoma",[52],"Early Phase 1","2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.474501Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT05996185","Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma",[12],"2026-08-26T02:16:52.995882Z","2026-05-05T02:43:28.341848Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT05967416","Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma",[27],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:27.815843Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07055477","A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)",[27],"2026-08-26T02:18:46.137046Z","2026-05-05T02:43:27.673466Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05010005","A Study of Ruxolitinib and Duvelisib in People With Lymphoma",[27],"2026-08-26T02:16:01.079019Z","2026-05-05T02:43:26.685721Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT05978141","A Registry for People With T-cell Lymphoma",[],"2026-08-26T02:16:20.336282Z","2026-05-13T02:55:06.403613Z",{"nct_id":86,"title":87,"phases":88,"status":89,"updated_at":90,"content_modified":91},"NCT07137481","Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:17.380174Z","2026-05-05T02:43:28.805067Z",{"nct_id":93,"title":94,"phases":95,"status":89,"updated_at":96,"content_modified":97},"NCT07691450","Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma",[27],"2026-08-26T02:16:42.787115Z","2026-07-19T19:36:05.157190Z",{"nct_id":99,"title":100,"phases":101,"status":102,"updated_at":103,"content_modified":104},"NCT03690011","Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T03:05:09.265674Z","2026-05-05T02:43:27.128098Z",[],[107,111,115,118,122,125,129,132,136,139,142,145,148,152,155,158,161],{"state":108,"count":109,"slug":110},"New York",9,"new-york",{"state":112,"count":113,"slug":114},"California",7,"california",{"state":116,"count":113,"slug":117},"Texas","texas",{"state":119,"count":120,"slug":121},"New Jersey",6,"new-jersey",{"state":123,"count":120,"slug":124},"Ohio","ohio",{"state":126,"count":127,"slug":128},"Massachusetts",5,"massachusetts",{"state":130,"count":127,"slug":131},"Michigan","michigan",{"state":133,"count":134,"slug":135},"Connecticut",4,"connecticut",{"state":137,"count":134,"slug":138},"Florida","florida",{"state":140,"count":134,"slug":141},"Georgia","georgia",{"state":143,"count":134,"slug":144},"Missouri","missouri",{"state":146,"count":134,"slug":147},"Pennsylvania","pennsylvania",{"state":149,"count":150,"slug":151},"Alabama",3,"alabama",{"state":153,"count":150,"slug":154},"Minnesota","minnesota",{"state":156,"count":150,"slug":157},"North Carolina","north-carolina",{"state":159,"count":150,"slug":160},"Oregon","oregon",{"state":162,"count":150,"slug":163},"Tennessee","tennessee"]